Quarterly report · Q1
2269.TEDINET S100RKR4
Period2023-04-01 → 2023-06-30
Filed2023-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥262.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥1.06T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥247.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥19.5bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥18.0bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥19.2bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥74.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥22.6bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥23.2bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.6bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥69.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥16.0bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥12.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥16.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.14T | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥409.7bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥384.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥762.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥751.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥725.4bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥84.1bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥81.0bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.9bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.4bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥85.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥5.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥36.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.0bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥54.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥22.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥41.59 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥247.39 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.87 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥151m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥151m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥310m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥218.7bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥218.6bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥147m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥15.2bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥44.2bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥44.2bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3m |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥4.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥262.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥262.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥151m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥19.8bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥140m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥140m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥278m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥204.4bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥204.3bn |
| jpcrp040300-q1r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥131m |
| jpcrp040300-q1r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥14.5bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥42.9bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥42.9bn |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥9m |
| jpcrp040300-q1r_E21902-000Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥247.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥247.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥140m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥18.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 498
| Item | Context | Value | Unit |
|---|---|---|---|
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -676000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -294000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -713000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 22271000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 22541000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 2024000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 835000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 20061000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 20106000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 64872000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 60939000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 84934000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 81045000000 | JPY |
| Discounted trade notes receivable | Prior1YearInstant | 2000000 | JPY |
| Discounted trade notes receivable | CurrentQuarterInstant | 12000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 204256000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 42875000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 247131000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 247131000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 131000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 9000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 140000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -140000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 204387000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 42884000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 247272000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -140000000 | JPY |
| Net sales | Prior1YTDDuration | 247131000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 14507000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 3815000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 18322000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -278000000 | JPY |
| Operating income | Prior1YTDDuration | 18044000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 218563000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 44170000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 262734000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 262734000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 147000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 3000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 151000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -151000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E21902-000FoodReportableSegmentsMember | 218711000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E21902-000PharmaceuticalsReportableSegmentsMember | 44173000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 262885000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -151000000 | JPY |
| Net sales | CurrentYTDDuration | 262734000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |